Mapping brain cells affected by Alzheimer's disease
Official title: Atlas for neuronal and glial cell types selectively vulnerable to proteinopathies during progression of Alzheimer's Disease
Funded at Salk Institute for Biological Studies · NIH-10849836 · Data updated 2026-11-12
This study looks at how specific brain cells are affected by Alzheimer's disease and why some areas of the brain are more impacted than others, which can help us understand the different symptoms people experience and find new ways to treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project start | June 1, 2023 |
| Project end | February 28, 2029 |
| Funding year | 2024 |
| Award (this year) | $2,789,418 |
| NIH project number | 5R01AG082151-02 |
| Project ID | NIH-10849836 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk due to genetic factors or age.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research investigates how certain types of brain cells, both neurons and glial cells, are selectively affected by Alzheimer's disease as it progresses. By examining the mechanisms behind this vulnerability, the study aims to understand why some brain regions are more impacted than others, which can lead to different symptoms in patients. The approach involves analyzing the interactions between these cells and the proteins associated with Alzheimer's, focusing on their responses over time and across various brain regions. This could provide insights into the disease's progression and potential therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for Alzheimer's disease, potentially slowing its progression or alleviating symptoms.
How similar studies have gone: Previous research has shown promising results in understanding the cellular mechanisms of Alzheimer's, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Salk Institute for Biological Studies
La Jolla, United States Active
Researchers
- Principal investigator: Lee, Kuo-Fen — Salk Institute for Biological Studies
- Study coordinator: Lee, Kuo-Fen
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.